Regarding vaccination against Covid-19, it is clear that antibody levels are declining six months after vaccination. However, T-cells are also thought to play an important role in providing protection.

The body's immune system, which develops after a common cold, can also be very helpful in keeping the corona away.

On Monday, a prestigious London research journal published a research report on the subject. According to a research report by Imperial College London, high levels of T-cells can provide protection against Covid-19 from the common cold. A team of scientists is conducting research on second generation vaccinations.

Antibodies are depleted six months after vaccination

Increase in T-cells after infection

The research began in September 2020. Accordingly, research was done on 52 people. In this research, the level of cross-reactive T-cells produced by the common cold was observed in these people infected with Kovi. It found that 26 people who were not infected had significantly higher levels of T-cells than those who were infected. However, Imperial did not say how long the protection against T-cells would last.

The report makes it clear that the common cold benefits

Research paper writer Dr. "We have found that high levels of pre-existing T cells in the body can protect against Covid-19 infection when infected with other human coronaviruses, such as the common cold," said Riya Kundu. Research published in Nature Communications suggests that the internal protein of SARS-Cavi-2 virus targeted by T-cells may provide an alternative target for vaccine manufacturers.

Current Covid-19 vaccines target spike proteins, which are mutated regularly, producing omikron-like types that reduce the effectiveness of the vaccine against therapeutic infections.

In contrast, we have identified very few endogenous proteins targeted by protective T-cells, said Professor Ajit Lalvani, co-author of the study. As a result, they are highly protected in various SARS-CoV-2 variants, including omicron. Newer vaccines that contain these protected, endogenous proteins will induce widespread protective T cell responses that should protect against current and future SARS-CoV-2 variants.